Alexander Fitzpatrick Sells Shares of ARS Pharmaceuticals

The Chief Legal Officer sold 3,355 shares in a planned transaction.

Written by Trueearnings · Published Jun 14, 2026, 2:00 AM EDT · Updated Jun 14, 2026, 8:00 PM EDT

Key Points

Alexander Fitzpatrick, Chief Legal Officer of ARS Pharmaceuticals, sold 3,355 shares at $10 each on June 12, 2026, in a planned transaction valued at $33,550.
Shares of ARS Pharmaceuticals traded near $9.76 with a market cap of about $969.2 million and a 52-week range of $6.66 to $18.90.
RA Capital Management holds 10,860,977 shares worth $87.2 million, while Millennium Management increased its position by 2,814,513 shares to 5,982,919 shares valued at $48 million.

On June 12, 2026, Alexander Fitzpatrick, the Chief Legal Officer of ARS Pharmaceuticals, Inc. (NasdaqGM: SPRY), sold 3,355 shares of the company. The shares were sold at a price of $10 each, amounting to a total transaction value of $33,550. This sale was part of a planned transaction.

Insider Buying and Selling at ARS Pharmaceuticals, Inc.

In addition to Alexander Fitzpatrick's sale, Eric Karas, Chief Commercial Officer, also executed several transactions on the same day. Karas sold 25,000 shares at $10 each in a planned transaction. He also bought 25,000 shares at $1.50 and sold another 25,000 shares at no cost. Earlier in the year, on January 2, Fitzpatrick and Karas each acquired 240,000 shares at no cost.

Other Institutional Activity in ARS Pharmaceuticals

RA Capital Management maintained its position in ARS Pharmaceuticals with 10,860,977 shares valued at approximately $87.2 million. OrbiMed Advisors also held steady with 8,288,510 shares worth about $66.6 million. Rubric Capital Management increased its holdings by 1,800,000 shares to a total of 8,000,000 shares, valued at $64.2 million. Millennium Management significantly boosted its stake by 2,814,513 shares, ending with 5,982,919 shares valued at $48 million. Meanwhile, BlackRock, Inc. trimmed its position slightly by 73,063 shares, leaving it with 5,012,254 shares worth roughly $40.2 million.

ARS Pharmaceuticals Stock Snapshot

Shares of ARS Pharmaceuticals traded near $9.76, with a market capitalization of approximately $969.2 million. The company has no meaningful P/E ratio as it isn't currently profitable. The stock's 52-week range is between $6.66 and $18.90, with a 50-day moving average of $8.44 and a 200-day moving average of $9.43. The company has a current ratio of 4.94 and a quick ratio of 4.65, indicating strong liquidity, but a high debt-to-equity ratio of 279.24.

Analysts Set New Price Targets

On May 28, 2026, Cantor Fitzgerald maintained its buy rating for ARS Pharmaceuticals, setting a price target of $30. Overall, the stock has a strong buy consensus with a target mean price of $28.80, based on 5 analyst opinions.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for severe allergic reactions. Its flagship product, neffy, is an innovative, needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Founded in 2015, the company is headquartered in San Diego, California, and led by CEO Richard E. Lowenthal. With approximately 154 employees, ARS Pharmaceuticals operates within the biotechnology industry.

Bottom Line

Alexander Fitzpatrick's planned sale of ARS Pharmaceuticals shares is part of routine insider trading activity. Investors often watch insider transactions for signals about management's view on the company's future. However, it's important to remember that these filings reflect past actions and may not indicate current sentiment. ARS Pharmaceuticals continues to draw interest from institutional investors and analysts, reflecting its position in the biotechnology sector.